ERBB2 and breast cancer: A more recent work also supports the idea of a subtype-dependent role of pluripotency markers in BC, since OCT4, SOX2 and NANOG were overexpressed in Her2 + BC tumors and associated with shorter overall survival (Yang et al. 2018).